Teleflex Expands CVC Portfolio in EMEA With New Launch: Stock to Gain?

Teleflex TFX recently launched its new Pressure Injectable Arrowg+ard Blue Plus MSB Procedure Kit in Europe, the Middle East and Africa (EMEA). This is regarded as a significant addition to the company’s market-leading portfolio of Centrally-Inserted Central Catheters.

Bạn đang xem: Teleflex Expands CVC Portfolio in EMEA With New Launch: Stock to Gain?

The Kit also features the Arrowg+ard Blue Plus CVC (central venous catheter), the only full-spectrum antimicrobial CVC that protects against gram-positive and gram-negative bacteria and fungi — the key infectious pathogens responsible for CLABSI4.

Since the announcement on Dec.10, Teleflex shares fell by 3.4%, finishing at $180.14 on Friday. On a promising note, these latest additions are expected to bolster the company’s Vascular Access portfolio, which has been gaining from robust adoption, including the peripheral and central access products. We expect the latest development to positively boost the market sentiment toward TFX stock.

Teleflex has a market capitalization of $8.37 billion. The company’s earnings yield of 7.76% compares favorably to the industry’s -4.85%. In the trailing four quarters, it delivered an average earnings surprise of 3.55%.

Developed after extensive market research and feedback from leading vascular access professionals, the Arrow MSB Procedure Kit provides clinicians with the essential components while adhering to maximal sterile barrier precautions. Key components, some of which are exclusive, include the Pressure Injectable CVC impregnated with Arrowg+ard Blue Plus Protection and the Arrow GlideWheel Advancer, which provides tactile feedback and finer control. The new dilator has demonstrated a reduction of penetration force by 48% to 72% when compared to a standard dilator.

The Kit also includes Nitinol Guidewire, which is kink-resistant compared to stainless steel, and a Transducer Cover and other critical items. These provide the clinician with the tools needed for taking maximal sterile barrier precautions as recommended in a range of respected clinical guidelines.

Image Source: Zacks Investment Research

Xem thêm : American Electric Power Stock: Income Portfolio With Mission Critical Utility (NASDAQ:AEP)

According to the European Centre for Disease Prevention and Control, nearly 28.4% of healthcare-associated bloodstream infections are reported as CVC-related. Alongside essential components for the placement of Centrally-Inserted Central Catheters, the all-in-one solution supports clinicians in adhering to national and international guidelines and other authoritative recommendations for reducing CLABSI, including the Centers for Disease Control and Prevention Category 1A & 1B recommendations, and Society for Hospital Epidemiology of America Guidelines.

Story Continues